Casdin Partners GP, LLC is Director & 10% Owner at STANDARD BIOTOOLS INC. (LAB). They have made 9 open-market trades across 3 companies since 2020, most recently 2025-11-25.
CIK 0001534260
7 open-market purchases totalling $40.8M since 2020, against 2 sales. Across 7 scored buys the stock is down 17.3% at ninety days, and 21.7 points behind the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| BLFS | 5,957,165 | $229.9M |
| LAB | 64,200,000 | $40.8M |
| TSVT | 1,630,000 | $8.2M |
| Total | $278.9M |
Shares reported on the most recent Form 4, priced at the 2025-11-26 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 43% | 57% | 29% |
| Avg Move | -0.7% | -3.3% | -17.3% |
| Alpha | -1.2% | -5.2% | -21.7% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LAB | BUY | 2025-11-24 | 2025-11-26 | $1.30 | $10.0M | -2.7% | -6.8% | -22.3% |
| LAB | BUY | 2025-11-07 | 2025-11-12 | $1.17 | $1.6M | +15.4% | +17.9% | +0.8% |
| BLFS | SELL | 2025-10-15 | 2025-10-17 | $28.55 | $21.4M | +0.6% | -12.3% | -10.6% |
| LAB | BUY | 2024-05-20 | 2024-05-22 | $2.57 | $1.5M | -5.6% | -28.0% | -30.6% |
| TSVT | SELL | 2024-03-21 | 2024-03-25 | $4.72 | $298K | -7.7% | -19.9% | -27.6% |
| TSVT | BUY | 2024-03-21 | 2024-03-25 | $5.03 | $4.7M | -7.7% | -19.9% | -27.6% |
| BLFS | BUY | 2023-08-09 | 2023-08-11 | $13.20 | $772K | -12.4% | +7.1% | -11.4% |
| BLFS | BUY | 2023-05-19 | 2023-05-23 | $22.21 | $2.2M | +5.4% | +4.4% | -51.3% |
| BLFS | BUY | 2020-05-14 | 2020-05-18 | $10.50 | $20.0M | +2.8% | +2.1% | +21.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.